Premium
Exelixis Inc Dl 01 (1EXEL)
BIT
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-06-01 | Dr. Sue Gail EckhardtIndependent Director | -9,81k | 491,97k | Automatic Disposition | 50,14 | 16,08k | -37,90% |
| 2026-06-01 | Mr. Jack L. WyszomierskiIndependent Director | -3,93k | 198,41k | Automatic Disposition | 50,55 | 284,38k | -1,36% |
| 2026-05-20 | Mr. Patrick Joseph HaleyExec. VP of Commercial | -32,11k | 1,60M | Vente | 49,81 | 357,64k | -8,24% |
| 2026-05-15 | Mr. Patrick Joseph HaleyExec. VP of Commercial | -33,27k | 1,70M | Sale to Issuer | 51,10 | 389,75k | -7,86% |
| 2026-05-15 | Dr. Michael M. MorrisseyCEO, President & Director | -128,50k | 6,57M | Sale to Issuer | 51,10 | 3,38M | -3,66% |
| 2026-05-18 | Dr. Michael M. MorrisseyCEO, President & Director | -124,05k | 0,00 | Other Disposition | - | 3,38M | -3,54% |
| 2026-05-15 | Dr. Brenda J. HeftiSenior VP & General Counsel | -6,41k | 327,60k | Sale to Issuer | 51,10 | 6,25k | -50,64% |
| 2026-05-18 | Mr. Christopher J. SennerExec. VP & CFO | -34,90k | 1,75M | Vente | 50,00 | 551,13k | -5,96% |
| 2026-05-18 | Dr. Brenda J. HeftiSenior VP & General Counsel | -6,63k | 332,64k | Automatic Disposition | 50,21 | 6,25k | -51,46% |
| 2026-05-15 | Mr. Christopher J. SennerExec. VP & CFO | -40,89k | 2,09M | Sale to Issuer | 51,10 | 551,13k | -6,91% |
| 2026-05-15 | Dr. Dana T. AftabExec. VP of Research & Development | -30,58k | 1,56M | Sale to Issuer | 51,10 | 238,06k | -11,38% |
| 2026-05-07 | Dr. Mary C. BeckerleIndependent Director | -3,86k | 186,82k | Vente | 48,45 | 0,00 | -100,00% |
| 2026-05-07 | Dr. Mary C. BeckerleIndependent Director | -3,86k | 97,21k | Derivative Exercise and Sale | 23,24 - 48,45 | 0,00 | - |
| 2026-05-07 | Dr. Maria C. FreireIndependent Director | -20,63k | 541,23k | Derivative Exercise and Sale | 19,77 - 46,00 | 91,01k | - |
| 2026-02-24 | Dr. Michael M. MorrisseyCEO, President & Director | -100,28k | 0,00 | Other Disposition | - | 2,01M | -4,76% |
| 2026-02-24 | Dr. Dana T. AftabExec. VP of Research & Development | -47,92k | 2,13M | Vente | 44,50 | 207,90k | -18,73% |
| 2026-02-19 | Dr. Dana T. AftabExec. VP of Research & Development | -29,87k | 1,32M | Vente | 44,35 | 255,82k | -10,46% |
| 2026-02-18 | Mr. Jack L. WyszomierskiIndependent Director | -20,63k | 500,17k | Derivative Exercise and Sale | 19,77 - 44,01 | 270,13k | - |
| 2026-02-18 | Mr. Jack L. WyszomierskiIndependent Director | -78,94k | 3,47M | Automatic Disposition | 44,01 | 270,13k | -22,61% |
| 2026-02-17 | Ms. Julie Anne SmithIndependent Director | -106,54k | 2,63M | Derivative Exercise and Sale | 18,19 - 44,50 | 10,78k | - |
| 2026-02-13 | Dr. Sue Gail EckhardtIndependent Director | -3,86k | 168,85k | Automatic Disposition | 43,79 | 0,00 | -100,00% |
| 2026-02-18 | Dr. Brenda J. HeftiSenior VP & General Counsel | -18,67k | 821,62k | Automatic Disposition | 44,01 | 6,08k | -75,42% |
| 2026-02-15 | Dr. Brenda J. HeftiSenior VP & General Counsel | -5,43k | 238,49k | Sale to Issuer | 43,92 | 6,08k | -47,16% |
| 2026-02-15 | Dr. Dana T. AftabExec. VP of Research & Development | -39,21k | 1,72M | Sale to Issuer | 43,92 | 285,69k | -12,07% |
| 2026-02-13 | Mr. Robert Lee OliverIndependent Director | -9,09k | 221,11k | Derivative Exercise and Sale | 19,28 - 43,61 | 2,22k | - |
| 2026-02-13 | Mr. Robert Lee OliverIndependent Director | -21,16k | 929,01k | Vente | 43,90 | 2,22k | -90,51% |
| 2026-02-13 | Dr. Michael M. MorrisseyCEO, President & Director | -494,70k | 10,98M | Derivative Exercise and Sale | 21,31 - 43,92 | 2,11M | - |
| 2026-02-17 | Dr. Michael M. MorrisseyCEO, President & Director | -371,13k | 0,00 | Other Disposition | - | 2,11M | -14,97% |
| 2026-02-13 | Mr. Christopher J. SennerExec. VP & CFO | -64,90k | 2,81M | Vente | 43,00 - 43,67 | 551,13k | -10,53% |
| 2026-02-15 | Mr. Christopher J. SennerExec. VP & CFO | -35,87k | 1,58M | Sale to Issuer | 43,92 | 551,13k | -6,11% |
| 2026-02-17 | Mr. Patrick Joseph HaleyExec. VP of Commercial | -67,81k | 2,95M | Vente | 43,50 - 43,84 | 0,00 | -100,00% |
| 2026-02-15 | Mr. Patrick Joseph HaleyExec. VP of Commercial | -31,48k | 1,38M | Sale to Issuer | 43,92 | 0,00 | -100,00% |
| 2026-01-15 | Mr. Christopher J. SennerExec. VP & CFO | -40,46k | 1,83M | Sale to Issuer | 45,23 | 585,40k | -6,46% |
| 2026-01-15 | Mr. Patrick Joseph HaleyExec. VP of Commercial | -32,33k | 1,46M | Sale to Issuer | 45,23 | 37,42k | -46,35% |
| 2026-01-15 | Dr. Dana T. AftabExec. VP of Research & Development | -27,25k | 1,23M | Sale to Issuer | 45,23 | 247,84k | -9,91% |
| 2026-01-15 | Dr. Michael M. MorrisseyCEO, President & Director | -139,52k | 6,31M | Sale to Issuer | 45,23 | 1,87M | -6,95% |
| 2025-11-10 | Farallon Capital Management, L.L.C.Société | 96,37k | 3,95M | Achat | 40,32 - 40,96 | 15,71M | 0,62% |
| 2025-11-13 | Farallon Capital Management, L.L.C.Société | -4,17M | 0,00 | Vente | 40,77 - 44,50 | 15,71M | -20,97% |
| 2025-11-25 | Caligan Partners, LPSociété | 27,53k | 1,19M | Achat | 43,12 | 1,55M | 1,80% |
| 2025-11-20 | Mr. Patrick Joseph HaleyExec. VP of Commercial | -72,23k | 3,05M | Vente | 41,77 - 42,58 | 0,00 | -100,00% |
| 2025-11-21 | Dr. Dana T. AftabExec. VP of Research & Development | -24,00k | 0,00 | Other Disposition | - | 215,31k | -10,03% |
| 2025-11-17 | Mr. Robert Lee OliverIndependent Director | -1,04k | 0,00 | Other Disposition | - | 23,38k | -4,27% |
| 2025-11-11 | Dr. Mary C. BeckerleIndependent Director | -5,78k | 108,68k | Derivative Exercise and Sale | 23,24 - 42,03 | 0,00 | - |
| 2025-11-11 | Dr. Mary C. BeckerleIndependent Director | -18,84k | 789,31k | Vente | 41,90 | 0,00 | -100,00% |
| 2025-11-11 | Dr. Michael M. MorrisseyCEO, President & Director | -341,55k | 0,00 | Other Disposition | - | 1,73M | -16,47% |
| 2025-11-11 | Dr. Dana T. AftabExec. VP of Research & Development | -48,38k | 2,06M | Vente | 42,50 | 239,31k | -16,82% |
| 2025-11-12 | Dr. Stelios PapadopoulosCo-Founder & Independent Chair of the Board | -100,00k | 4,36M | Vente | 43,55 | 1,18M | -7,82% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
